弱视双眼家庭治疗:获益稳定维持一年
这项非劣效随机对照试验的长期随访观察研究纳入43名4至不足9岁弱视儿童,初始接受CureSight双眼眼动追踪家庭治疗16周。治疗后12周弱视眼视力较基线改善0.27±0.14 logMAR且维持,1年时较治疗结束部分回退0.085±0.1 logMAR,但较基线残余获益0.20±0.14 logMAR仍有统计学意义。结论认为无需额外治疗,视力与立体视获益可维持至1年。
要点
- 治疗后12周弱视眼视力较基线改善0.27±0.14 logMAR,与治疗结束时无变化。
- 治疗后1年较治疗结束回退0.085±0.1 logMAR,但较基线残余获益0.20±0.14 logMAR仍有统计学意义。
- 12周和1年时立体视与双眼视力较基线均维持改善,与治疗结束时无变化。
核心结论
- CureSight双眼治疗后的视力和立体视获益在1年时无需额外治疗仍得以维持。
研究设计与样本
- 前瞻性、多中心、非随机长期随访观察研究,随访对象来自一项非劣效随机对照试验。
- 43名4至不足9岁患有屈光参差性、小角度斜视性或混合机制弱视的儿童初始接受CureSight治疗16周(NCT05185076)。
- 38名未接受额外弱视治疗的患者在治疗后12周接受评估,27名在治疗后1年接受评估。
主要发现
- 治疗后12周,弱视眼视力较基线改善0.27±0.14 logMAR(P< .0001),与治疗结束时相比无变化(P > .05)。
- 治疗后1年,弱视眼视力较治疗结束回退0.085±0.1 logMAR(P = .001),但较基线残余获益0.20±0.14 logMAR仍有统计学意义(P < .0001)。
- 治疗后12周和1年,立体视与双眼视力较基线均维持改善(P < .0001),与治疗结束时相比无变化(P > .05)。
- 弱视复发(较治疗结束恶化≥2 logMAR水平)在治疗后12周为2/38例(5.3%),在治疗后1年为5/27例(20.4%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the long-term outcomes of a noninferiority randomized controlled trial (RCT) with a binocular eye-tracking-based home treatment (CureSight; NovaSight, Ltd.) in patients with amblyopia. DESIGN: Prospective, multicenter, nonrandomized, long-term follow-up observational study of an RCT. METHODS: Forty-three children 4 to <9 years of age with anisometropic, small-angle strabismic, or mixed-mechanism amblyopia were initially treated for 16 weeks (NCT05185076) with CureSight. In this planned observational follow-up study, 38 patients with no additional amblyopia treatment were evaluated at 12 weeks post-treatment, and 27 were evaluated at 1-year post-treatment. The main outcome measures were visual acuity (VA), stereoacuity, and amblyopia recurrence at 12- and 52-week post-treatment. RESULTS: At 12-week post-treatment, improvement in amblyopic eye VA was maintained vs baseline (0.27 ± 0.14 logMAR, P< .0001), with no change vs the end-of-treatment visit (P > .05). At 1 year there was a partial reduction in the amblyopic eye VA gain of 0.085±0.1 logMAR compared to end-of-treatment (P = .001), but the residual gain of 0.20±0.14 logMAR compared to baseline was statistically significant (P < .0001). Gains in stereoacuity and binocular VA were maintained vs baseline at both 12-weeks and 1-year post-treatment (P < .0001), with no change vs end-of-treatment (P > .05). Amblyopia recurrence (a worsening of ≥2 logMAR levels compared with end-of-treatment) occurred in 2/38 patients at 12-weeks post-treatment (5.3%), and in 5/27 patients at 1-year post-treatment (20.4%). CONCLUSIONS: VA and stereopsis gains following binocular treatment with CureSight were maintained at 1 year without additional treatment.
引用
- Wygnanski-Jaffe T, Moshkovitz A, Kushner BJ, et al. Binocular Home Treatment for Amblyopia: Gains Stable for One Year. Am J Ophthalmol. 2024. PMID: 38360334. doi:10.1016/j.ajo.2024.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。